-

ACRO Applauds Release of Cures 2.0 Draft Legislation

WASHINGTON--(BUSINESS WIRE)--The Association of Clinical Research Organizations (ACRO) congratulates Representatives Diana DeGette (D-CO) and Fred Upton (R-MI) on the release of the Cures 2.0 discussion draft, an update to the landmark 21st Century Cures Act. The Cures Act took significant steps to modernize the clinical trial ecosystem, and ACRO welcomes this effort to build upon that progress.

ACRO has been especially committed to increasing diversity and inclusion in clinical trials to improve outcomes for vulnerable populations, and expanding the use of safe and effective decentralized clinical trials to expand patient access and reduce barriers to participation.

“Representing companies that provide services and technologies for a majority of clinical trials worldwide, ACRO was pleased to be an information resource for the 21st Century Cures Act in 2015, and we congratulate Representatives DeGette and Upton on the release of the Cures 2.0 discussion draft,” said Doug Peddicord, ACRO’s Executive Director. “We very much look forward to providing input on key issues, including increasing diversity in clinical trials, expanding the use of patient experience and real-world data, and developing a national strategy for future pandemics.”

ACRO looks forward to working with Reps. DeGette and Upton, and their colleagues in the Senate, on advancing these solutions into law.

For further comment or press inquiries, please contact Sophia McLeod, ACRO’s Director of Government Relations, at smcleod@acrohealth.org.

About ACRO

The Association of Clinical Research Organizations (ACRO) represents clinical research and technology companies that provide a variety of specialized tools and services to support the development of new pharmaceuticals, biologics, and medical devices. Through its member companies, ACRO works to improve the quality, efficiency, and safety of biomedical research. ACRO member companies operate in more than 100 countries across the globe and conduct or support the conduct of a majority of clinical trials across all therapeutic areas.

Contacts

Sophia McLeod
smcleod@acrohealth.org

Industry:

Association of Clinical Research Organizations

Release Versions
English

Contacts

Sophia McLeod
smcleod@acrohealth.org

More News From Association of Clinical Research Organizations

ACRO Announces 2026 Officers

WASHINGTON--(BUSINESS WIRE)--Today, ACRO announced that its Board of Directors elected Cassandra “Sandy” Kennedy, Chief Quality, Regulatory Affairs, and Sustainability Officer at Fortrea, as Chair of the Association, effective January 1, 2026. Gadi Saarony, Chief Executive Officer at Advarra, was elected Vice-Chair. In addition, the Board of Directors elected Marco Capasso, Chief Legal and Risk Officer, Secretary to the Board at Advarra as Secretary of the Association, and Ari Feldman, Senior V...

ACRO Announces Recipients of Diversity & Inclusion Site Resource Grants

WASHINGTON--(BUSINESS WIRE)--Today, ACRO announced the seven clinical research sites that will receive grant funding as part of the ACRO Diversity and Inclusion Site Resource Grants Program. The site grant awardees include: Brooklyn Clinical Research – New York K2 Medical Research – Florida Nebraska Cancer Specialists – Nebraska Preferred Primary Care Physicians – Pennsylvania Randomize Now – Georgia Smart Cures Clinical Research – California Superior Clinical Research – North Carolina With thi...

ACRO Announces 2025 Officers and New Members

WASHINGTON--(BUSINESS WIRE)--ACRO today announced that its Board of Directors elected Jim Reilly, Executive Vice President, Development Cloud Strategy at Veeva, as Chair of the Association, effective January 1, 2025. Cassandra “Sandy” Kennedy, Chief Quality, Regulatory Affairs, and Sustainability Officer at Fortrea, was elected Vice-Chair. In addition, the Board of Directors re-elected Mike Crowley, Chief Administrative Officer, General Counsel, and Secretary at Parexel, as Secretary of the Ass...
Back to Newsroom